CD274 and neoplasm: This heterogeneity in terms of antibodies/platforms in the anatomic pathology departments has the advantage to confer versatility in the assessment of PD-L1 expression in different tumor types and organs (e.g., lung cancer) but requires an appropriate validation for their employment in different clinical settings.